Tom Powles: This seems an ambitious accelerated approval in UC

Tom Powles, Director of Barts Cancer Center, recently shared on X:

“TDXD received FDA accelerated approval in HER2 IHC 3+ treatment-refractory tumors. While HER 1-3+ is common in UC, 3+ is <25% (RR-50% n=16). New treatments are welcome. Ongoing testing is needed. This seems an ambitious accelerated approval in UC.”

Read further.
Source: Tom Powles/X